Say Hello!
Don’t be shy.

 
0333 323 1843
 

[email protected]

 

BioCity Group HQ:
Pennyfoot Street
Nottingham
NG1 1GF

Psyros Diagnostics awarded £400K Innovate UK Smart Award to accelerate development of their ground-breaking ultra-sensitive IVD technology

Psyros Diagnostics awarded £400K Innovate UK Smart Award to accelerate development of their ground-breaking ultra-sensitive IVD technology

Coronary heart disease is one of the leading causes of death within the UK. Every day over 2500 patients present at A&E departments across the UK with chest pain, indicative of a suspected heart attack. Of these, only 20% will have a confirmed heart attack. Diagnosis often takes several hours after arriving at A&E while healthcare professionals wait for test results to be processed by the hospital laboratory. Faster identification of these patients will save lives and improve the outcomes for patients, ensuring they receive rapid treatment. Timely discharge of the remaining 80%, who are not suffering a heart attack, minimises unnecessary hospital admissions and costs to the NHS.

During a heart attack, a protein called troponin (Tn) is released into the bloodstream from the damaged heart muscle. BioCity Pre-Accelerator graduate, Psyros are developing a game-changing point-of-care technology able to measure the extremely low levels of Tn needed by clinicians to make critical rule in/rule out care decisions as quickly as possible. Our highly innovative and patent-pending system is designed to detect these ultra-low Tn levels from a small drop of blood taken from the finger by measuring the individual Tn molecules, giving accurate and actionable results within 10 mins. We have already shown feasibility of our disruptive approach through our successful Innovate UK precision medicine feasibility award project. This project builds on the success of that feasibility work by demonstrating the required functional clinical performance.
Psyros Diagnostics Ltd.

Psyros Diagnostics was formed in 2018 by a team of experienced in-vitro diagnostics developers that acquired key assets from the Novartis Near-Patient Testing Unit. Psyros recognise the unmet need for rapid and ultra-sensitive testing at the point of need to improve health outcomes and quality of life for patients. The team have a proven track record in clinical diagnostics development, from initial concept phase through to CE marking in both a start-up and a multinational healthcare company environment. Psyros are rapidly developing their system to address the unmet clinical need for patients for Acute Cardiac and other applications requiring ultra-sensitive testing.